IHC Inspiration Healthcare Group Plc

TIDMIHC

Inspiration Healthcare Group PLC

21 January 2020

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Inspiration Healthcare

EC certificates extended to May 2024

As part of Inspiration Healthcare's preparation for the new European Union Medical Device Regulation (MDR) which comes into force in May 2020, the Company confirms that it has now received its new EC Certificate for its products (excluding the recently acquired Viomedex products) to extend until May 2024 their CE marking under the existing Medical Device Directive.

As a result, all Inspiration Healthcare's products will not be adversely affected by the implementation of MDR. The Company can continue to promote the products where a valid EC Certificate is accepted whilst it applies to its Notified Body (TÜV SÜD) to review its technical documentation under the new regulation.

Commenting today, Neil Campbell, Inspiration Healthcare's Chief Executive said:

"We are pleased to have extended the EC Certificate which allows us to continue to promote the products whilst we review our technical documentation and apply for conformity to the new Medical Device Regulation. Our new and innovative products in our R&D pipeline are already being developed with MDR in mind and we expect a seamless transition to the MDR in due course."

Enquiries:

 
 Inspiration Healthcare            Tel: 01455 840555 
  Group plc 
  Neil Campbell, Chief Executive 
  Officer 
  Mike Briant, Chief Financial 
  Officer 
 Nominated Adviser & Broker        Tel: 0207 397 8900 
  Cenkos Securities plc 
  Stephen Keys 
  Mark Connelly 
  Cameron MacRitchie 
 Cadogan PR                        Tel: 07771 713608 
  Alex Walters 
  alex.walters@cadoganpr.com 
 

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.

Through investment in research and development the Company has 6 key own brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally the Company has its own range of products for maintaining normothermia pre- during and post-surgery.

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the UK and Ireland the Company has a direct sales team selling Inspiration Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

Further information on Inspiration Healthcare can be seen at www.inspiration-healthcare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAFLFLDLRIIFII

(END) Dow Jones Newswires

January 21, 2020 02:01 ET (07:01 GMT)

Inspiration Healthcare (LSE:IHC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Inspiration Healthcare (LSE:IHC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024